NASDAQ
INM
Last Price
US $1.56
KEY FIGURES
MKT CAP
$2.8M
EPS
TTM
$-2.45
PEG
TTM
N/M
P/E
TTM
N/M
P/S
TTM
1.57x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
InMed Pharmaceuticals Inc. cash flow to debt ratio of -769.07% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
InMed Pharmaceuticals Inc.'s free cash flow has decreased 11.03% from $-7.00M last year to $-7.77M, signaling decreasing performance
Financial stability - Healthy debt to equity ratio.
InMed Pharmaceuticals Inc.'s debt to equity ratio is 0.06, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
InMed Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.10 last year to 0.06 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
InMed Pharmaceuticals Inc. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
InMed Pharmaceuticals Inc.'s interest coverage ratio is -496.36, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
InMed Pharmaceuticals Inc.'s profit margin has decreased (47.60%) in the last year from -166.94% to -246.41%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
InMed Pharmaceuticals Inc.'s short-term assets of $17.53M exceed its short-term liabilities of $2.51M
Decreasing performance - ROA.
InMed Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
InMed Pharmaceuticals Inc.'s return on equity of -72.72%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
InMed Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
InMed Pharmaceuticals Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
InMed Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
InMed Pharmaceuticals Inc. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
InMed Pharmaceuticals Inc.'s yearly earnings has decreased 6.34% since last year from $-7.68M to $-8.16M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
InMed Pharmaceuticals Inc.'s yearly revenue has decreased -21.41% since last year from $6.29M to $4.94M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -135.77% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
InMed Pharmaceuticals Inc.'s 3-year revenue CAGR of 65.55% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
InMed Pharmaceuticals Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
InMed Pharmaceuticals Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
InMed Pharmaceuticals Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
InMed Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
InMed Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
InMed Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
InMed Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
InMed Pharmaceuticals Inc. has a price-to-book ratio of 0.92x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
InMed Pharmaceuticals Inc. has a price-to-sales ratio of 1.57x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-72.72%
Return on equity
ROIC: -135.77%
Valuation History
0.00X
Price to Earnings
EV/EBITDA: 0.19X
Cash flow
Profit margin
-
(FY vs FY)
EBITDA Y/Y
3.83%
(FY vs FY)
Cash flow Y/Y
-0.92%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $1.56
—
Default assumptions
EBITDA Multiple
Fair Value
Market $1.56
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.